Hidemi Takahashi

Publication Activity (10 Years)

Years Active: 2017-2019
Publications (10 Years): 6

Top Topics

Dendritic Cells

Immune Response

Mycobacterium Tuberculosis

Top Venues

Cancer immunology, immunotherapy : CII

Scientific reports

Journal of immunology (Baltimore, Md. : 1950)

This page only lists publications with an associated author ORCID identifier.

Publications

Yuji Tomita, Eri Watanabe, Masumi Shimizu, Yasuyuki Negishi, Yukihiro Kondo, Hidemi Takahashi
Induction of tumor-specific CD8+ cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cells. Cancer immunology, immunotherapy : CII 68 (10) (2019)
Michiyuki Yonekawa, Masumi Shimizu, Atsushi Kaneko, Jiro Matsumura, Hidemi Takahashi
Suppression of R5-type of HIV-1 in CD4+ NKT cells by Vδ1+ T cells activated by flavonoid glycosides, hesperidin and linarin. Scientific reports 9 (1) (2019)
Hidehiko Narazaki, Takeshi Yanagihara, Masumi Shimizu, Hidemi Takahashi, Yasuhiko Itoh
Pediatric immunoglobulin A complex secretory component deficiency. Pediatrics international : official journal of the Japan Pediatric Society 60 (7) (2019)
Yohei Otsuka, Eri Watanabe, Eiji Shinya, Sadayuki Okura, Hidehisa Saeki, Teunis B H Geijtenbeek, Hidemi Takahashi
Differentiation of Langerhans Cells from Monocytes and Their Specific Function in Inducing IL-22-Specific Th Cells. Journal of immunology (Baltimore, Md. : 1950) 201 (10) (2018)
Takushi Masu, Masanori Atsukawa, Katsuhisa Nakatsuka, Masumi Shimizu, Daishu Miura, Taeang Arai, Hirotomo Harimoto, Chisa Kondo, Keiko Kaneko, Seiji Futagami, Chiaki Kawamoto, Hidemi Takahashi, Katsuhiko Iwakiri
Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. PloS one 13 (12) (2018)
Hideki Kogo, Masumi Shimizu, Yasuyuki Negishi, Eiji Uchida, Hidemi Takahashi
Suppression of murine tumour growth through CD8+ cytotoxic T lymphocytes via activated DEC-205+ dendritic cells by sequential administration of α-galactosylceramide in vivo. Immunology 151 (3) (2017)